Key clinical point: Docetaxel Prednisone, and Pazopanib combo was tolerable at full doses and showed promising efficacy in relatively poor risk patients with metastatic castration-resistant prostate cancer (mCRPC).
Major finding: Objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and overall survival was 18.6 months (95% CI: 11.8 and 22.2).
Study details: 36 men with mCRPC were treated over 6 dose levels in a 2-site phase 1b Department of Defense Prostate Cancer Clinical Trials Consortium trial of docetaxel, prednisone, and pazopanib, once daily and ongoing androgen deprivation therapy and prophylactic pegfilgrastim.
George D, et al. Prostate. 2019 Sep 9. doi: 10.1002/pros.23899.